Dr. David Miklos is an experienced hematopoietic cell transplant clinician and the Clinical Director of Stanford University’s Center for Cancer Cell Therapy. His laboratory research focuses on B lymphocyte biology, tumor immunology, chronic graft versus host disease, and CAR-T therapies. He has translated his laboratory insights to improve allogeneic hematopoietic cell transplantation and CAR-T therapy, and his research significantly contributed to two FDA approvals:
1) Yescarta for patients with aggressive lymphoma that has failed two therapies
2) Ibrutinib for patients with cGVHD that has failed prior therapy

Dr. Miklos was an undergraduate at the University of Notre Dame. He earned his MD and a PhD in Genetics at Yale Medical School before training as a hematologist – oncologist and bone marrow transplant clinician at Brigham and Woman’s hospital and Dana-Farber Cancer Institute at Harvard University. David Joined Stanford University in 2004.